Trial Profile
The effect of adalimumab on cardiovascular and metabolic risk factors in the treatment of patients with moderate to severe psoriasis vulgaris in comparison to a standard therapy (fumaric acid) [Der Einfluss von Adalimumab auf kardiovaskuläre und metabolische Risikofaktoren in der Therapie von Patienten mit mittelschwerer bis schwerer Psoriasis vulgaris im Vergleich zu einer Standardtherapie (Fumarsäureester)]
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 May 2015
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Fumaric acid
- Indications Plaque psoriasis
- Focus Adverse reactions
- Acronyms CASTIP
- 16 May 2015 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
- 27 Jun 2011 New trial record